Apatinib+IE + IE
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effect of Drug
Conditions
Effect of Drug, Drug, Toxicity
Trial Timeline
Mar 1, 2022 → Nov 26, 2023
NCT ID
NCT05277480About Apatinib+IE + IE
Apatinib+IE + IE is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Effect of Drug. The current trial status is completed. This product is registered under clinical trial identifier NCT05277480. Target conditions include Effect of Drug, Drug, Toxicity.
What happened to similar drugs?
2 of 4 similar drugs in Effect of Drug were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05277480 | Phase 2 | Completed |
Competing Products
20 competing products in Effect of Drug